The magistral framework.
Peptika preparations exist under a specific legal carve-out of European pharmaceutical law: Article 5(1) of Directive 2001/83/EC. This page explains what that means, why it matters, and how cross-border prescription recognition fits in.
The magistral carve-out.
The default rule in European medicines law is that a medicine cannot be placed on the market without a Marketing Authorisation. Article 5(1) creates a narrow but well-defined exception: medicines compounded in response to a bona fide unsolicited order, prepared for an individual patient, on the prescription of a healthcare professional do not require Marketing Authorisation.
This is the same legal framework that allows hospital pharmacies across the EU to prepare individualised medications for specific patients — anaesthetic mixes, paediatric dosages, allergen-free formulations, custom oncology doses. Peptika operates within that framework.
Cross-border recognition.
Directive 2011/24/EU on the application of patients' rights in cross-border healthcare establishes that medical prescriptions issued in one EU/EEA member state are recognised in any other EU/EEA member state.
This means a prescription signed by an EU-licensed Peptika physician can be filled by a compounding pharmacy in another EU member state. Combined with magistral preparation, this allows the network to operate Europe-wide while remaining fully compliant with national pharmaceutical authorities.
Sterile compounding.
All Peptika preparations are compounded in cleanrooms certified under EU-GMP Annex 1 Grade A/B. Annex 1 is the European regulatory standard for the manufacture of sterile medicinal products.
A Qualified Person (QP) — a regulated role under Articles 48 and 51 of Directive 2001/83/EC — releases each batch only after every quality test has passed. The QP is personally accountable for batch release under European pharmaceutical law.
Quality by reference.
Each batch is tested against the European Pharmacopoeia. Sterility follows EP 2.6.1 (membrane filtration), endotoxins follow EP 2.6.14 (LAL assay), heavy metals follow EP 2.4.8 (ICP-MS). Identity and purity are confirmed by HPLC + mass spectrometry against in-house specifications, with a purity threshold of > 98%.
The Certificate of Analysis for every batch you receive is uploaded to your patient dashboard and matches the batch number printed on each vial.
Magistral is not a loophole.
Not a substitute for licensed medicines
When a peptide has an approved Marketing Authorisation in the EU for a specific indication, that licensed product is the right choice. Magistral preparations are for clinical needs the licensed market does not address.
Not anonymous shipping
No preparation is compounded without a valid prescription. No package is shipped to anyone other than the named patient on the prescription. There is no "guest checkout".
Not promotion to the public
We do not advertise peptide therapies as cures. We describe what they are, what we know, and what the licensed framework allows. Your physician judges whether a protocol is clinically appropriate.